Qiagen, NL0012169213

Qiagen stock heads into the open after a 2.27% drop

Published on 09/21/2026 at 06:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

At the close on September 18, 2026, Qiagen stock finished at USD 43.37 on the NYSE, down 2.27% on the day. The shares traded within their recent range and remain below the year-to-date starting level, while an extraordinary general meeting has been scheduled for November.

Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte, klinisches Laborlicht
Qiagen N.V. (NL0012169213) Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte im klinischen Labor, Illustration mit AI erstellt.

Qiagen stock closed at USD 43.37 on the New York Stock Exchange on September 18, 2026, down 2.27% from the prior session in USD terms. Compared with about USD 47.34 at the beginning of 2026, the shares were roughly 8.4% lower year-to-date on that date, underscoring a weaker performance than the broader US equity benchmarks.

September 18, 2026 in numbers

Qiagen N.V. (ISIN NL0012169213) ended trading on September 18, 2026 at USD 43.37 on the New York Stock Exchange, with the daily loss of 2.27% implying that the prior close stood at approximately USD 44.38 per share. Per closing data for that session, the stock remained comfortably above its 52-week low while still trading well below the recent high, indicating that the move took place within an established range rather than at an extreme level. Market commentary noted that Qiagen shares were about 8.4% below their level at the start of 2026 on that date, highlighting a weaker year-to-date path than major US indices such as the S&P 500, which have shown gains over the same period.

According to a market wrap published by Ad-hoc-news on September 20, 2026, the latest decline came after earlier sessions in which an earnings beat was seen as already priced in, with limited upside perceived in the shares despite the stronger results. The same report pointed out that Qiagen stock maintained a market capitalization of around USD 8.94 billion as of September 18, 2026, providing context for the size of the move in relation to the company’s overall equity value. Within that trading day, the shares fluctuated in a narrow intraday band with the close positioned between the high and low, and turnover remained in line with recent averages, suggesting normal liquidity conditions rather than an exceptional spike in activity.

Extraordinary meeting and upcoming agenda today

Looking ahead from today, Qiagen has set an Extraordinary General Meeting of Shareholders for November 6, 2026 at 2:00 p.m. CET, where investors will be asked to vote on the appointment of Jonathan M. Pratt to the Managing Board after he took over as Chief Executive Officer on September 1, 2026, as stated in a company announcement distributed via BusinessWire on September 21, 2026. This governance-focused event falls outside the immediate five-trading-day window but underscores a key leadership change that may frame investor expectations around Qiagen’s strategic direction during upcoming sessions.

Disclaimer...

en | NL0012169213 | QIAGEN | boerse | 70141516 | bgmi